SYNAPTIGEN Group
Biotechnology Research • 
Wilmington, North Carolina, United States • 1-10 Employees
Company overview
| Headquarters | Wilmington, North Carolina, United States |
| NAICS | 541714 |
| Keywords | Pharmacokinetics, Business Development, Venture Capital Consulting, Patient Advocacy, Cro Consulting, Biotech Consulting, Pharmaceutical Branding, Drug Development Consulting, Biotech Branding, Cro Branding, Cro Sales Training, Clinical Research Podcast, Clinical Research Service Provider, Drug Development Go-To-Resource |
| Founded | 2024 |
| Employees | 1-10 |
Key Contact at SYNAPTIGEN Group
Erik K. Volland
Director, Business Operationa
About SYNAPTIGEN Group
SYNAPTIGEN Group provides consulting services from target identification to market approval as the go-to-resource in drug development, nonclinical, clinical research, patient integration and commercial service provider solutions. With decades of industry experience, we pull together drug developers, service providers and insights to bring therapies to patients faster – one connection at a time. OUR MISSION: At SYNAPTIGEN, our mission is to connect passionate and dedicated teams to deliver innovative solutions that accelerate the journey of therapies to patients. By fostering collaboration, embracing efficiency, and embodying a relentless commitment to excellence, we aim to transform lives through faster, more effective solutions.
SYNAPTIGEN Group revenue & valuation
| Annual revenue | $427,775 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,400,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
SYNAPTIGEN Group has never raised funding before.
Belgium
Australia
Luxembourg
Finland
BrazilFrequently asked questions
4.8
40,000 users
